MDACC Study No:2011-0167 ( NCT No: NCT01323751)
Title:A Phase I/II, Open-label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed-Refractory Multiple Myeloma
Principal Investigator:Robert Orlowski
Treatment Agent:ACY-1215; Bortezomib; Dexamethasone
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of ACY-1215 (ricolinostat) that can be given alone and in combination with
dexamethasone and Velcade (bortezomib) to patients with MM. The safety of this
drug combination will also be studied.

Part 1 of this study, where patients were given ACY-1215 alone, has ended.
Parts 2 and 3, where ACY-1215 is given with dexamethasone and bortezomib are
still ongoing. Part 2 enrollment will be completed before Part 3 begins.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:ACY-1215
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Acetylon Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Orlowski
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults